THE WORLD ANTI-DOPING CODE

INTERNATIONAL
STANDARD

PROHIBITED LISTJANUARY 2020

The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French.
In the event of any conflict between the English and French versions, the English version shall prevail.
This List shall come into effect on 1 January 2020

SUBSTANCES & METHODSPROHIBITED AT ALL TIMES(IN- AND OUT-OF-COMPETITION)
IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL
BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND
PROHIBITED METHODS M1, M2 AND M3.

PROHIBITED SUBSTANCES
S0 NON-APPROVED SUBSTANCES

Calusterone;
Clostebol;
Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol);
Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy17α-methylandrosta-1,4-dien-3-one);
Desoxymethyltestosterone (17α-methyl-5α-androst2-en-17β-ol and 17α-methyl-5α-androst-3-en-17β-ol);
Drostanolone;
Epiandrosterone (3β-hydroxy-5α-androstan-17-one);
Epi-dihydrotestosterone (17β-hydroxy-5β-androstan-3one);
Epitestosterone;
Ethylestrenol (19-norpregna-4-en-17α-ol);Fluoxymesterone;
Formebolone;
Furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5αandrostan-17β-ol);
Gestrinone;
Mestanolone;
Mesterolone;
Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien3-one);
Metenolone;
Methandriol;
Methasterone (17β-hydroxy-2α,17α-dimethyl-5αandrostan-3-one);
Methyl-1-testosterone (17β-hydroxy-17α-methyl-5αandrost-1-en-3-one);
Methylclostebol;
Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien3-one);
Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en3-one);
Methyltestosterone;
Metribolone (methyltrienolone, 17β-hydroxy-17αmethylestra-4,9,11-trien-3-one);
Mibolerone;
Nandrolone (19-nortestosterone);
Norboletone;

Any pharmacological substance which is notaddressed by any of the subsequent sections of theList and with no current approval by any governmental
regulatory health authority for human therapeutic use(e.g. drugs under pre-clinical or clinical development
or discontinued, designer drugs, substances approved
only for veterinary use) is prohibited at all times.

S1 ANABOLIC AGENTS

Anabolic agents are prohibited.

1. ANABOLIC ANDROGENIC STEROIDS (AAS)
when administered exogenously, including but not limitedto:
1-Androstenediol (5α-androst-1-ene-3β,17β-diol);
1-Androstenedione (5α-androst-1-ene-3,17-dione);
1-Androsterone (3α-hydroxy-5α-androst-1-ene-17-one);
1-Epiandrosterone (3β-hydroxy-5α-androst-1-ene-17-one);
1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one);
4-Androstenediol (androst-4-ene-3β,17β-diol);
4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3one);
5-Androstenedione (androst-5-ene-3,17-dione);
7α-hydroxy-DHEA;
7β-hydroxy-DHEA;
7-Keto-DHEA;
19-Norandrostenediol (estr-4-ene-3,17-diol);
19-Norandrostenedione (estr-4-ene-3,17-dione);
Androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5αandrostan-3-one);
Androstenediol (androst-5-ene-3β,17β-diol);
Androstenedione (androst-4-ene-3,17-dione);
Bolasterone;
Boldenone;
Boldione (androsta-1,4-diene-3,17-dione);2

Norclostebol (4-chloro-17β-ol-estr-4-en-3-one);
Norethandrolone;
Oxabolone;
Oxandrolone;
Oxymesterone;
Oxymetholone;
Prasterone (dehydroepiandrosterone, DHEA,3β-hydroxyandrost-5-en-17-one);
Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'Hpyrazolo[3,4:2,3]-5α-androstane);
Quinbolone;
Stanozolol;
Stenbolone;
Testosterone;
Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17αpregna-4,9,11-trien-3-one);
Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one);

S2 PEPTIDE HORMONES, GROWTH FACTORS,RELATED SUBSTANCES, AND MIMETICSThe following substances, and other substances withsimilar chemical structure or similar biological effect(s),are prohibited:

1.	Erythropoietins (EPO) and agents affecting erythropoiesis,including, but not limited to:
1.1 Erythropoietin-Receptor Agonists, e.g.
Darbepoetins (dEPO);
Erythropoietins (EPO);
EPO based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)];EPO-mimetic agents and their constructs(e.g. CNTO-530, peginesatide).
1.2 Hypoxia-inducible factor (HIF) activating agents, e.g.
Cobalt;Daprodustat (GSK1278863);
Molidustat (BAY 85-3934);
Roxadustat (FG-4592);
Vadadustat (AKB-6548);
Xenon.

and other substances with a similar chemical structure
or similar biological effect(s).
2. OTHER ANABOLIC AGENTS
Including, but not limited to:
Clenbuterol, selective androgen receptor modulators[SARMs, e.g. andarine, LGD-4033 (ligandrol), enobosarm(ostarine) and RAD140], tibolone, zeranol and zilpaterol.

1.3 GATA inhibitors, e.g.
K-11706.
1.4 TGF-beta (TGF-β) signalling inhibitors, e.g.
Luspatercept;
Sotatercept.
1.5 Innate repair receptor agonists, e.g.
Asialo EPO;
Carbamylated EPO (CEPO).

3S3 BETA-2 AGONISTS

2. Peptide Hormones and their Releasing Factors,
2.1 Chorionic Gonadotrophin (CG) and Luteinizing
Hormone (LH) and their releasing factors in males,e.g. Buserelin, deslorelin, gonadorelin, goserelin,
leuprorelin, nafarelin and triptorelin;

All selective and non-selective beta-2 agonists,
including all optical isomers, are prohibited.
Including, but not limited to:
Fenoterol;
Formoterol;
Higenamine;
Indacaterol;
Olodaterol;
Procaterol;
Reproterol;
Salbutamol;
Salmeterol;
Terbutaline;
Tretoquinol (trimetoquinol);Tulobuterol;Vilanterol.

2.2 Corticotrophins and their releasing factors, e.g.
Corticorelin;
2.3 Growth Hormone (GH), its fragments and releasing
factors, including, but not limited to:Growth Hormone fragments, e.g.
AOD-9604 and hGH 176-191;
Growth Hormone Releasing Hormone (GHRH) andits analogues, e.g.
CJC-1293, CJC-1295, sermorelin and tesamorelin;
Growth Hormone Secretagogues (GHS), e.g.
Lenomorelin (ghrelin) and its mimetics, e.g.
Anamorelin, ipamorelin, macimorelin andtabimorelin; GH-Releasing Peptides (GHRPs), e.g.
Alexamorelin, GHRP-1, GHRP-2 (pralmorelin),
GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin(hexarelin).

Except:• Inhaled salbutamol: maximum 1600 micrograms over
24 hours in divided doses not to exceed 800 micrograms
over 12 hours starting from any dose;• Inhaled formoterol: maximum delivered dose of
54 micrograms over 24 hours;• Inhaled salmeterol: maximum 200 micrograms over24 hours.

3. Growth Factors and Growth Factor Modulators,
including, but not limited to:
Fibroblast Growth Factors (FGFs);
Hepatocyte Growth Factor (HGF);
Insulin-like Growth Factor-1 (IGF-1) and its analogues;
Mechano Growth Factors (MGFs);
Platelet-Derived Growth Factor (PDGF);
Thymosin-β4 and its derivatives e.g. TB-500;
Vascular-Endothelial Growth Factor (VEGF);

The presence in urine of salbutamol in excess of 1000 ng/mLor formoterol in excess of 40 ng/mL is not consistent withtherapeutic use of the substance and will be considered as anAdverse Analytical Finding (AAF) unless the Athlete proves,through a controlled pharmacokinetic study, that theabnormal result was the consequence of a therapeutic dose(by inhalation) up to the maximum dose indicated above.

and other growth factors or growth factor modulators
affecting muscle, tendon or ligament protein synthesis/
degradation, vascularisation, energy utilization,
regenerative capacity or fibre type switching.

4S4 HORMONE AND METABOLIC

landogrozumab, stamulumab).

MODULATORS

5. Metabolic modulators:
5.1 Activators of the AMP-activated protein kinase(AMPK), e.g. AICAR, SR9009; and Peroxisome
Proliferator Activated Receptor δ (PPARδ) agonists,
e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)
phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid
(GW1516, GW501516);
5.2 Insulins and insulin-mimetics;
5.3 Meldonium;
5.4 Trimetazidine.

The following hormone and metabolic modulators
are prohibited:
1. Aromatase inhibitors including, but not limited to:2-Androstenol (5α-androst-2-en-17-ol);
2-Androstenone (5α-androst-2-en-17-one);
3-Androstenol (5α-androst-3-en-17-ol);
3-Androstenone (5α-androst-3-en-17-one);
4-Androstene-3,6,17 trione (6-oxo);
Aminoglutethimide;
Anastrozole;
Androsta-1,4,6-triene-3,17-dione (androstatrienedione);
Androsta-3,5-diene-7,17-dione (arimistane);
Exemestane;
Formestane;
Letrozole;
Testolactone.

S5 DIURETICS AND MASKING AGENTS

The following diuretics and masking agents areprohibited, as are other substances with a similar chemical
structure or similar biological effect(s).
Including, but not limited to:• Desmopressin; probenecid; plasma expanders,e.g. intravenous administration of albumin, dextran,hydroxyethyl starch and mannitol.
• Acetazolamide; amiloride; bumetanide; canrenone;
chlortalidone; etacrynic acid; furosemide; indapamide;
metolazone; spironolactone; thiazides, e.g. Bendroflumethiazide, chlorothiazide and hydrochlorothiazide;
triamterene and vaptans, e.g. Tolvaptan.
Except:• Drospirenone; pamabrom; and ophthalmic use ofcarbonic anhydrase inhibitors (e.g. Dorzolamide,brinzolamide);• Local administration of felypressin in dental
anaesthesia.

2.	Selective estrogen receptor modulators (SERMs)
including, but not limited to:Bazedoxifene;
Ospemifene;
Raloxifene;
Tamoxifen;
Toremifene.
3.	Other anti-estrogenic substances including, but notlimited to:
Clomifene;
Cyclofenil;
Fulvestrant.
4.	Agents preventing activin receptor IIB activation
including, but not limited, to:

The detection in an Athlete’s Sample at all times orIn-Competition, as applicable, of any quantity of
the following substances subject to threshold
limits: formoterol, salbutamol, cathine, ephedrine,methylephedrine and pseudoephedrine, in conjunction
with a diuretic or masking agent, will be considered as
an Adverse Analytical Finding (AAF) unless the Athlete
has an approved Therapeutic Use Exemption (TUE) forthat substance in addition to the one granted for thediuretic or masking agent.

Activin A-neutralizing antibodies;
Activin receptor IIB competitors such as:
Decoy activin receptors (e.g. ACE-031);
Anti-activin receptor IIB antibodies (e.g. Bimagrumab);
Myostatin inhibitors such as:Agents reducing or ablating myostatin expression;
Myostatin-binding proteins (e.g. Follistatin, myostatinpropeptide);
Myostatin-neutralizing antibodies (e.g. Domagrozumab,
5

PROHIBITED METHODS
M1 MANIPULATION OF BLOOD AND

M3

BLOOD COMPONENTS

The following are prohibited:

GENE AND CELL DOPING

The following, with the potential to enhance sport
performance, are prohibited:

1.	The Administration or reintroduction of any quantity ofautologous, allogenic (homologous) or heterologous
blood, or red blood cell products of any origin into thecirculatory system.

1.	The use of nucleic acids or nucleic acid analogues that
may alter genome sequences and/or alter gene
expression by any mechanism. This includes but is not
limited to gene editing, gene silencing and gene transfer
technologies.

2.	Artificially enhancing the uptake, transport or deliveryof oxygen.
Including, but not limited to:
Perfluorochemicals; efaproxiral (RSR13) and modified
haemoglobin products, e.g. Haemoglobin-based blood
substitutes and microencapsulated haemoglobin
products, excluding supplemental oxygen by inhalation.

3. The use of normal or genetically modified cells.

3.	Any form of intravascular manipulation of the blood orblood components by physical or chemical means.

M2 CHEMICAL AND PHYSICALMANIPULATION

The following are prohibited:
1. Tampering, or Attempting to Tamper, to alter theintegrity and validity of Samples collected during
Doping Control.
Including, but not limited to:Sample substitution and/or adulteration, e.g. Addition ofproteases to Sample.
2. I ntravenous infusions and/or injections of more thana total of 100 mL per 12 hour period except for thoselegitimately received in the course of hospitaltreatments, surgical procedures or clinical diagnostic
investigations.

6SUBSTANCES & METHODSPROHIBITED IN-COMPETITIONIN ADDITION TO THE CLASSES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CLASSES
ARE PROHIBITED IN-COMPETITION:

PROHIBITED SUBSTANCES
b: Specified Stimulants:
Including, but not limited to:

S6 STIMULANTS

All stimulants, including all optical isomers, e.g.
d- and l- where relevant, are prohibited.

3-Methylhexan-2-amine (1,2-dimethylpentylamine);
4-Methylhexan-2-amine (methylhexaneamine);
4-Methylpentan-2-amine (1,3-dimethylbutylamine);
5-Methylhexan-2-amine (1,4-dimethylpentylamine);
Benzfetamine;
Cathine**;Cathinone and its analogues, e.g. mephedrone,
methedrone, and α - pyrrolidinovalerophenone;
Dimetamfetamine (dimethylamphetamine);
Ephedrine***;Epinephrine**** (adrenaline);
Etamivan;Etilamfetamine;
Etilefrine;
Famprofazone;
Fenbutrazate;
Fencamfamin;
Heptaminol;
Hydroxyamfetamine (parahydroxyamphetamine);
Isometheptene;
Levmetamfetamine;
Meclofenoxate;
Methylenedioxymethamphetamine;
Methylephedrine***;Methylphenidate;
Nikethamide;
Norfenefrine;
Octodrine (1,5-dimethylhexylamine);
Octopamine;
Oxilofrine (methylsynephrine);
Pemoline;
Pentetrazol;
Phenethylamine and its derivatives;
Phenmetrazine;
Phenpromethamine;
Propylhexedrine;
Pseudoephedrine*****;

Stimulants include:
a: Non-Specified Stimulants:
Adrafinil;
Amfepramone;
Amfetamine;
Amfetaminil;
Amiphenazole;
Benfluorex;
Benzylpiperazine;
Bromantan;
Clobenzorex;
Cocaine;Cropropamide;
Crotetamide;
Fencamine;
Fenetylline;
Fenfluramine;
Fenproporex;
Fonturacetam [4-phenylpiracetam (carphedon)];Furfenorex;
Lisdexamfetamine;
Mefenorex;
Mephentermine;
Mesocarb;
Metamfetamine(d-);
p-methylamfetamine;
Modafinil;
Norfenfluramine;
Phendimetrazine;
Phentermine;
Prenylamine;
Prolintane.
A stimulant not expressly listed in this section
is a Specified Substance.
7S7 NARCOTICS

Selegiline;
Sibutramine;Strychnine;
Tenamfetamine (methylenedioxyamphetamine);
Tuaminoheptane;

The following narcotics, including all optical isomers, e.g.
d- and l- where relevant, are prohibited:
Buprenorphine;
Dextromoramide;
Diamorphine (heroin);
Fentanyl and its derivatives;
Hydromorphone;
Methadone;
Morphine;
Nicomorphine;
Oxycodone;
Oxymorphone;
Pentazocine;
Pethidine.

and other substances with a similar chemical structure
or similar biological effect(s).
Except:• Clonidine;• Imidazole derivatives for dermatological, nasal orophthalmic use and those stimulants included in the2020 Monitoring Program*.
* 	Bupropion, caffeine, nicotine, phenylephrine,phenylpropanolamine, pipradrol, and synephrine: Thesesubstances are included in the 2020 Monitoring Program, andare not considered Prohibited Substances.
** 	Cathine: Prohibited when its concentration in urine is greaterthan 5 micrograms per milliliter.
*** 	Ephedrine and methylephedrine: Prohibited when theconcentration of either in urine is greater than 10 micrograms
per milliliter.
****	Epinephrine (adrenaline): Not prohibited in local administration,e.g. nasal, ophthalmologic, or co-administration with local
anaesthetic agents.
***** P seudoephedrine: Prohibited when its concentration in urine
is greater than 150 micrograms per milliliter.

S8 CANNABINOIDS
All natural and synthetic cannabinoids are prohibited, e.g.
• In cannabis (hashish, marijuana) and cannabis products• Natural and synthetic tetrahydrocannabinols (THCs)• Synthetic cannabinoids that mimic the effects of THC
Except:• Cannabidiol.

S9 GLUCOCORTICOIDS

All glucocorticoids are prohibited when administeredby oral, intravenous, intramuscular or rectal routes.
Including but not limited to:
Betamethasone;
Budesonide;Cortisone;
Deflazacort;
Dexamethasone;
Fluticasone;
Hydrocortisone;
Methylprednisolone;
Prednisolone;
Prednisone;
Triamcinolone.
8

SUBSTANCES PROHIBITED
IN PARTICULAR SPORTS

P1 BETA-BLOCKERS

Beta-blockers are prohibited In-Competition only, inthe following sports, and also prohibited Out-of-Competition
where indicated.
• Archery (WA)*• Automobile (FIA)• Billiards (all disciplines) (WCBS)• Darts (WDF)• Golf (IGF)• Shooting (ISSF, IPC)*• Skiing/Snowboarding (FIS) in ski jumping, freestyleaerials/halfpipe and snowboard halfpipe/big air• Underwater sports (CMAS) in constant-weight apnoea
with or without fins, dynamic apnoea with and without
fins, free immersion apnoea, Jump Blue apnoea,
spearfishing, static apnoea, target shooting, and variableweight apnoea.
*Also prohibited Out-of-Competition

Including, but not limited to:
Acebutolol;
Alprenolol;
Atenolol;
Betaxolol;
Bisoprolol;
Bunolol;
Carteolol;
Carvedilol;
Celiprolol;
Esmolol;Labetalol;
Metipranolol;
Metoprolol;
Nadolol;
Oxprenolol;
Pindolol;
Propranolol;
Sotalol;
Timolol.

9www.wada-ama.org